Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19-CAR-T Cells for Relapsed/Refractory Autoimmune Diseases
NCT06420154Phase 1Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in systemic lupus erythematosus (SLE), Sjogren's syndrome, systemic sclerosis (SSc) and 3 more, sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: Incidence of dose-limiting toxicity at 28 days, Laboratory abnormalities and type, frequency and severity of adverse events at 1 year and 1 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)Sjogren's syndromesystemic sclerosis (SSc)inflammatory myopathy (IIM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06420154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06420154.